share_log

AIM Vaccine Insider Ups Holding By 27% During Year

AIM Vaccine Insider Ups Holding By 27% During Year

AIm疫苗內部人士在全年內將持股增加27%
Simply Wall St ·  07/18 18:49

From what we can see, insiders were net buyers in AIM Vaccine Co., Ltd.'s (HKG:6660 ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it.

據我們所見,內部人士是AiM疫苗有限公司的淨買家。”s (HKG: 6660) 在過去的 12 個月中。也就是說,內部人士收購該股票的數量比出售的數量還要多。

While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.

儘管在長期投資中,內幕交易並不是最重要的事情,但我們認爲完全忽視內幕交易是愚蠢的。

The Last 12 Months Of Insider Transactions At AIM Vaccine

AiM Vaccine 過去 12 個月的內幕交易

In the last twelve months, the biggest single purchase by an insider was when Executive Chairman & CEO Yan Zhou bought HK$1.4m worth of shares at a price of HK$6.65 per share. That means that an insider was happy to buy shares at above the current price of HK$6.50. Their view may have changed since then, but at least it shows they felt optimistic at the time. In our view, the price an insider pays for shares is very important. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. The only individual insider to buy over the last year was Yan Zhou.

在過去的十二個月中,內部人士最大的一次收購是執行主席兼首席執行官周燕以每股6.65港元的價格購買了價值140萬港元的股票。這意味着內部人士樂於以高於當前6.50港元的價格購買股票。從那以後,他們的觀點可能發生了變化,但至少這表明他們當時感到樂觀。我們認爲,內部人士爲股票支付的價格非常重要。總的來說,當內部人士以高於當前的價格購買股票時,它會引起我們的注意,因爲這表明他們認爲即使價格更高,也值得買入。去年唯一買入的內部人士是周巖。

Yan Zhou bought a total of 1.33m shares over the year at an average price of HK$7.86. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

周燕全年共購買了133萬股股票,平均價格爲7.86港元。你可以在下面看到過去 12 個月的內幕交易(公司和個人)的直觀描述。如果你想確切地知道誰賣了、賣了多少以及何時出售,只需點擊下圖!

big
SEHK:6660 Insider Trading Volume July 18th 2024
SEHK: 6660 內幕交易量 2024 年 7 月 18 日

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.

還有許多其他公司有內部人士購買股票。你可能不想錯過這份內部人士正在收購的被低估的小盤股公司的免費清單。

Insider Ownership Of AIM Vaccine

AiM 疫苗的內部所有權

For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. AIM Vaccine insiders own about HK$2.2b worth of shares (which is 28% of the company). Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

對於普通股股東來說,值得檢查一下公司內部人士持有多少股票。我們通常希望看到相當高的內部所有權水平。AiM Vaccine內部人士擁有價值約22億港元的股份(佔該公司28%的股份)。大多數股東會很高興看到這種內部所有權,因爲這表明管理層的激勵措施與其他股東非常一致。

So What Do The AIM Vaccine Insider Transactions Indicate?

那麼 AiM 疫苗內幕交易表明了什麼?

Insider purchases may have been minimal, in the last three months, but there was no selling at all. That said, the purchases were not large. But insiders have shown more of an appetite for the stock, over the last year. It would be great to see more insider buying, but overall it seems like AIM Vaccine insiders are reasonably well aligned (owning significant chunk of the company's shares) and optimistic for the future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. In terms of investment risks, we've identified 2 warning signs with AIM Vaccine and understanding them should be part of your investment process.

在過去的三個月中,內幕購買量可能微乎其微,但根本沒有拋售。也就是說,購買量並不大。但是,在過去的一年中,內部人士對該股表現出了更大的興趣。很高興看到更多的內幕收購,但總體而言,AiM Vaccine的內部人士似乎相當一致(擁有公司的大部分股份),對未來持樂觀態度。因此,雖然了解內部人士在買入或賣出方面的所作所爲很有幫助,但了解特定公司面臨的風險也很有幫助。在投資風險方面,我們已經確定了AiM Vaccine的兩個警告信號,並了解它們應該成爲您投資過程的一部分。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,來看看這份有趣的公司的免費清單吧。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對這篇文章有反饋嗎?擔心內容嗎?直接聯繫我們。或者,發送電子郵件至 editorial-team@simplywallst.com

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論